Biotechnology company Morphogen-IX recently announced that it will be further developing MGX292 as its treatment candidate for pulmonary arterial hypertension (PAH). The company’s decision is supported by previous preclinical studies that have shown the potential of MGX292, a signaling protein analogue, as a safe and effective therapy for PAH.
News
PhaseBio Pharmaceuticals started dosing its investigational compound PB1046 in patients with pulmonary arterial hypertension (PAH) in a Phase 2b clinical trial. The first patient to receive the therapy was dosed by Murali Chakinala, MD, professor of medicine at the Washington University School of Medicine (WUSM), and director of…
A subset of bone marrow cells known as proangiogenic cells (PACs) may drive the development of pulmonary arterial hypertension (PAH), according to a study that also showed that blocking a specific serotonin receptor may be a therapeutic strategy for the disease. The study, “Bone Marrow-Derived Proangiogenic…
The Stanford University School of Medicine is the first clinical site for a Phase 2 trial testing levosimendan as a potential treatment for pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF), Tenax Therapeutics recently announced. Ejection fraction is the amount of blood that the…
A receptor protein present in immune cells is a potential target for treating pulmonary hypertension (PH), according to a new study. The findings — based on patient lung tissue and animal experiments – showed a link between low levels of Toll-like receptor 3 (TLR3) and the disease. Published in the…
Arena Pharmaceuticals and United Therapeutics have reached a global licensing agreement for the pulmonary arterial hypertension (PAH) therapy candidate ralinepag. Ralinepag (APD811) is a next-generation, selective prostacyclin receptor agonist designed for oral delivery. Prostacyclin, produced by cells lining the walls of blood vessels, is a vasodilator (a widener of blood…
Pulmonary arterial hypertension (PAH) patients with an enlarged right side of the heart show higher pulmonary arterial pressures and increased resistance to blood flow compared to healthy controls, a new study reports. The study “Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a…
Revatio (sildenafil) in low doses is safe and can be of benefit to children with pulmonary hypertension (PH), particularly those with early lung disease, a study reports. With this work, the researchers weighed in on a controversy, coming down in favor of the treatment. Revatio is approved to treat adults with pulmonary…
INOpulse is advancing in a number of clinical trials as a potential treatment of pulmonary hypertension (PH) associated with several lung diseases, Bellerophon Therapeutics reported in a recent announcement. The company is currently developing INOpulse to treat PH associated with chronic obstructive pulmonary disease (COPD), interstitial lung…
The severity of pulmonary hypertension (PH) increases the risk of fetus death, although mortality among PH pregnant women is low, according to a Chinese review study. The study, “Pregnancy and pulmonary hypertension: An exploratory analysis of risk factors and outcomes” was published in the journal Medicine. Pregnancy induces…
Treprostinil is a therapy that works to reduce pulmonary artery narrowing in people with pulmonary arterial hypertension (PAH) by preventing artery wall remodeling processes. That finding comes from a research study investigating the medicine’s molecular effects using patient lung artery cells suggests. Treprostinil appears to…
Transgelin, a smooth muscle protein, is abundant in patients with irreversible pulmonary arterial hypertension (PAH) secondary to congenital heart disease and may contribute to PAH progression, a study reports. The study, “Transgelin as a potential target in the reversibility of pulmonary arterial hypertension secondary to congenital heart disease,” was…
